Background: The 2010 New York State (NYS) HIV Testing Law requires that primary care providers routinely offer HIV testing to patients aged 13-64 years, regardless of risk, and link individuals with HIV to medical care. School-based health centers (SBHCs) are in a position to offer HIV screening to a significant proportion of youth. One year after the law went into effect, we conducted a study to assess whether NYS SBHCs implemented these provisions.
Methods: Medical providers from 83 NYS SBHCs, serving students age 13 and older, participated in a Web-based survey regarding school-based health center capacity for and implementation of routine HIV testing, linkage to care, attitudes, and barriers.
Results: On-site HIV testing was reported to be available at 71% of SBHCs. Linkages to age-appropriate HIV care were reported to be available at 85% of SBHCs. The routine offer of HIV testing for eligible students was reported to be implemented at 55% of SBHCs. Forty-one percent reported that HIV testing was offered to at least half of eligible students during the 2010-2011 school year. New York City and high school providers were more likely to report the routine offer of HIV testing, on-site testing, linkages to care, perceive students as willing to test, indicate fewer barriers, and report having offered testing to a majority of eligible students in the previous year.
Conclusions: Many SBHCs have adopted key provisions of the amended NYS HIV Testing Law. Additional assistance may be needed to achieve full implementation; however, especially among SBHCs serving younger populations and those located outside New York City.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/QAI.0000000000000393 | DOI Listing |
Background: Seeking sexual partners in men who have sex with men (MSM) venues has been regarded as a high-risk behavior for HIV among MSM. Nevertheless, with the implementation of venue-based interventions and the change in the way MSM seek sexual partners, the continued status of MSM venues as the HIV risk factor remains inconclusive. This study endeavors to delve into this ambiguity by examining the MSM sexual contact network (SCN) as a foundation.
View Article and Find Full Text PDFArch Razi Inst
June 2024
Hepatitis Research Center, Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are known as the most common blood-borne viral infections worldwide. Individuals referring to drop-in centers (DICs) are considered high-risk people exposed to infection with blood-borne viruses. The purpose of this study was to investigate the prevalence of HIV, HBV, and HCV infections among women referred to DICs in Lorestan Province, western Iran.
View Article and Find Full Text PDFTransgend Health
December 2024
Fenway Health, The Fenway Institute, Boston, Massachusetts, USA.
Purpose: Transgender and nonbinary adults (TNB) are disproportionately burdened by sexually transmitted infections (STI) and the human immunodeficiency virus (HIV). This study investigated whether gender-affirming hormone therapy was associated with TNB adults' odds of screening for STI and HIV.
Methods: Longitudinal data came from the electronic medical records of TNB primary care patients receiving care at two community health centers located in Boston, Massachusetts, and New York City, New York, between January 2013 and December 2019.
Cureus
November 2024
Department of Radiology, Pain Relief and Palliative Care Unit, Aretaeio Hospital/National and Kapodistrian University of Athens School of Medicine, Athens, GRC.
Introduction HIV stigma levels are high in Greece. HIV stigma hinders testing, healthcare access, and treatment adherence, often leading to non-disclosure. The discloser navigates challenges by balancing the confidant's potential reactions, ranging from rejection and discrimination to the benefits of increased intimacy and liking.
View Article and Find Full Text PDFACG Case Rep J
January 2025
Internal Medicine, Marshall University Medical Center, Huntington, WV.
Long-acting injectable formulation of cabotegravir/rilpivirine (CAB/RPV) is a promising novel maintenance therapy for HIV infection. However, coinfection with active hepatitis B virus (HBV) infection is a contraindication to initiating this therapy. Despite guidelines, patients with HBV immunity can still contract acute HBV infection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!